Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
Persistent Atrial Fibrillation | Paroxysmal Atrial FibrillationThis study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 to 80
Participation Criteria
Key inclusion criteria:
* A diagnosis of recurrent symptomatic paroxysmal or persistent AF
* Failure or intolerance of at least one antiarrhythmic drug (AAD) Class I or III
Key exclusion criteria:
* Long-standing persistent AF (sustained \>12 months)
* Atrial fibrillation secondary to a reversible cause or of non-cardiac origin
* History of thromboembolic events within the past six months
* Myocardial infarction (MI)/percutaneous coronary intervention (PCI) within the last three months
* Any cardiac surgery within the previous six months
* Prior left atrial ablation or surgical procedure
* Presence of an implanted cardiac device
* Body mass index (BMI) \>40 kg/m\^2
* Left ventricular ejection fraction (LVEF) \<35%
* Anterior-posterior left atrial (LA) diameter \>55mm
Study Location
McGill University Health Centre
McGill University Health CentreMontréal, Quebec
Canada
Contact Study Team
St.Paul's Hospital
St.Paul's HospitalVancouver, British Columbia
Canada
Contact Study Team
- Study Sponsored By
- Kardium Inc.
- Participants Required
- More Information
- Study ID:
NCT05462145